Cartesian Therapeutics (RNAC) Long-Term Debt Issuances (2020 - 2023)
Cartesian Therapeutics' (RNAC) quarterly Long-Term Debt Issuances came in at $24.9 million in Q3 2023, up 24483.33% on a QoQ basis from -$102000.0 in Q4 2020.
Cartesian Therapeutics (RNAC) Long-Term Debt Issuances (2020 - 2023) Analysis & Trends
Cartesian Therapeutics (RNAC) has 2 years of Long-Term Debt Issuances data on file, last reported at $24.9 million in Q3 2023.
- On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $24.9 million in Q3 2023; TTM through Sep 2023 was $24.9 million, a 24483.33% increase from a year earlier, with the FY2020 full-year figure at $24.7 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q3 2023 stood at $24.9 million, up from -$102000.0 in the prior quarter.
- Over the last five years, Long-Term Debt Issuances for RNAC reached as high as $24.9 million in Q3 2023 and fell as low as -$102000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cartesian Therapeutics | 226.07 Mn | 226.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 24.87 Mn |
| Sep 30, 2023 | 24.87 Mn |
| Dec 31, 2020 | -102,000.00 |
| Dec 31, 2020 | -102,000.00 |